Investigating the role of CD63 in microglia TAU clearance

Active Grant Awarded

Award ID
F31AG099275
Recipient
Awarding agency
Obligated
$46,320

Award facts

Assistance listing
93.866 Aging Research
Completion date 9% complete
Place of performance
Boston, MA 02111, USA

Award details come from USAspending.gov.

Description

Abstract
Establishing effective disease-modifying treatments for alzheimer's disease (ad) remains a major medical challenge. Neuron death and cognitive decline in ad correlate strongly with the pathological spread and accumulation of hyperphosphorylated TAU aggregates. Emerging evidence implicates microglia, the primary phagocytes of the brain, as critical drivers of disease progression. Typically, microglia phagocytose and degrade TAU in the lysosome to maintain brain homeostasis. In ad, microglial endolysosomal network (ELN) becomes dysfunctional thus hindering their ability to clear TAU aggregates via the lysosome. Alternatively, microglia can release undigested TAU via exosomes which infect healthy neurons and propagate TAU pathology. The mechanisms regulating microglial ELN function, and disease-associated dysfunction, are incompletely understood. Tetraspanin protein CD63 plays a cell-type dependent role in regulating ELN- associated endocytosis, protein targeting to lysosomes and exosomes, and exosome secretion. CD63 becomes significantly upregulated in microglia in ad and other tauopathies, however, IT is unknown whether and how CD63 regulates ELN function in microglia in disease. Preliminary data suggest CD63 negatively regulates microglial phagocytosis, lysosome function, and exosome biogenesis. Therefore, disease-associated upregulation of CD63 might impair microglial clearance of TAU, promoting disease progression. We hypothesize that CD63 deletion in microglia will enhance TAU clearance by improving phagocytosis and lysosomal degradation, concomitantly limiting TAU spread via exosome release. To test this hypothesis, aim 1 will utilize CD63-knockout and microglia-specific CD63-rescue primary microglia culture, TAU aggregate treatment, exosome isolation, and elisa to investigate how CD63 regulates microglia clearance of TAU via phagocytosis, lysosome-mediated degradation, and exosome release in vitro. We expect CD63 deletion in microglia to enhance TAU phagocytosis and lysosome-mediated degradation. Aim 2 will utilize single-cell RNA sequencing, mouse models of tauopathy, and viral induction of TAU spreading to examine how CD63-deletion alters microglia ELN in tauopathy, as well as TAU spreading throughout the brain. Successful completion of this research will advance our understanding of microglial contributions to ad and related tauopathies, informing therapeutic strategies targeting disease progression. IT will also provide a strong foundation for my development as an independent investigator focused on glial involvement in neurodegeneration.

Transactions

Action Obligated Date
Amendment $0
Original award $46,320

Quick answers

Who received award F31AG099275?

F31AG099275 was awarded to Trustees Of Tufts College by National Institute on Aging (National Institutes of Health) on September 14, 2026.

How much is award F31AG099275 worth?

$46,320 has been obligated on F31AG099275.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award